KalVista Pharmaceuticals (KALV) said Tuesday it has finished enrolling participants in the Konfident-KID clinical study of experimental oral plasma kallikrein inhibitor sebetralstat for children aged two to 11 with hereditary angioedema.
Strong demand led the company to enroll about 36 participants instead of the original 24, reaching the recruitment goal a year ahead of schedule, the company said.
Initial findings are expected later in this year, while the company plans to submit a supplemental New Drug Application by mid-2026, it added.
The trial, spanning seven countries in North America, Europe, and Asia, aims to gather safety, pharmacokinetic, and efficacy data for up to one year, according to the company.
Shares of the company were down about 2% in recent trading.
Price: 12.01, Change: -0.24, Percent Change: -1.96
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。